Compare McKesson Corporation (MCK) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Payoneer Global Inc — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Payoneer Global Inc trades at $7.19 (market cap $2.43B). The key difference: McKesson Corporation is far larger — about 44.6× Payoneer Global Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Payoneer Global Inc for 61 Days on average.
| MCK | PAYO | |
|---|---|---|
Market Cap | $108.46B | $2.43B |
Volume | 712,607 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $995.69 | $7.18 |
52-Week Low | $725.17 | $4.27 |
Typical Hold Time | 74 Days | 61 Days |
Enterprise Value | $115.00B | $2.17B |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Payoneer (PAYO) trades at $7.16, up 0.14% on the day, with a bullish technical signal from moving averages and a mixed earnings history including a Q2 2026 miss. Revenue grew to $821.16M in 2025, but net income declined to $73.19M, compressing margins. The company renewed its partnership with Etsy through 2029 and faces ongoing legal scrutiny regarding its proposed acquisition by Nuvei.
The outlook is cautious; while analyst consensus is 60% buy-rated and cash flow trends are positive, risks include earnings volatility, acquisition uncertainty, and competitive pressures. Investors should weigh strong institutional interest against execution challenges and margin pressures for medium-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
